Amaran to construct a new plant and drug trial center
Amaran Biotechnology, a Taipei-based drug manufacturer, has revealed plans to invest $33.41m in the construction of a factory and a research center at Hsinchu Biomedical Science Park.
The research center at the new facility, which is likely to start operations in the first quarter of 2014, will be used to carry out clinical trials and manufacture OBI Pharma-developed drugs, according to the company.
Production at the factory will focus on botulinum toxin type A biosimilar, along with other generic protein drugs.
The new facilities will be built under level 3 biosafety conditions and is claimed to be the country's first plant to be established in line with such conditions.
OBI Pharma chairman Michael Chang and Ruentex Group chairman Samuel Yin formed Amaran in 2010, as part of joint investment agreement.
An OBI Pharma official was quoted by Taipei Times as saying, "If our OBI-822/821 drug -- which is used to treat breast cancer -- can pass the third stage of clinical trials in Taiwan, the new factory will manufacture the drug for us."
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250